Secondary malignancies and survival of FCR‐treated patients with chronic lymphocytic leukemia in Central Europe

This is the first large‐scale cross‐country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central Eu...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer medicine (Malden, MA) Vol. 12; no. 2; pp. 1961 - 1971
Main Authors:	Kósa, Fruzsina, Nečasová, Tereza, Špaček, Martin, Giannopoulos, Krzysztof, Hus, Iwona, Jurková, Tereza, Koriťáková, Eva, Chrápavá, Marika, Nováčková, Martina, Katinová, Ivana, Krejčí, Denisa, Jujka, Adam, Mátrai, Zoltán, Vályi‐Nagy, István, Robak, Tadeusz, Doubek, Michael
Format:	Journal Article
Language:	English
Published:	United States John Wiley & Sons, Inc 01-01-2023 John Wiley and Sons Inc Wiley
Subjects:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Cancer Chemotherapy Chronic lymphocytic leukemia CLL population Codes Cyclophosphamide - therapeutic use Data collection Decision making Diagnosis Disease-Free Survival Drugs Europe - epidemiology FCR therapy Hospitals Humans Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology Lymphoma Male Malignancy Medical prognosis Melanoma Patients Registration Retrospective Studies Risk factors Rituximab - therapeutic use secondary malignancy Statistical analysis Survival Tumors Europe Poland Czech Republic Hungary Central Europe secondary malignancy CLL population FCR therapy survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!